Introduction {#S1}
============

M/K~v~7 channels are extensively distributed in central and peripheral nerve system ([@B8]) and play a crucial role in the stabilization of membrane potential and modulation of neuronal excitability ([@B29]). For example, M/K~v~7 channels determine the resting membrane potential (RMP) of dorsal root ganglion (DRG) neurons ([@B20]) and the firing patterns of action potentials (APs) in superior cervical ganglion (SCG) sympathetic neurons ([@B30]); loss-of-function mutations of M/K~v~7 channel subunits located in the brain result in epilepsy ([@B6]; [@B55]; [@B2]).

Importance of M/K~v~7 channels have been demonstrated in a variety of pathological conditions. In the brain, inhibition of M/K~v~7 channels by M1 muscarinic receptor in basolateral amygdala promotes fear memory consolidation ([@B65]); augmentation of M/K~v~7 channels reduces cerebral ischemic stroke-induced brain injury ([@B5]). In the peripheral nerve system, inhibition of M/K~v~7 currents of DRG neurons contributes to acute inflammatory pain induced by pro-inflammatory factors such as proteases ([@B35]) and bradykinin ([@B37]); down-regulation of M/K~v~7 expression in DRG neurons mediates chronic inflammatory pain ([@B42]), neuropathic pain ([@B48]; [@B31]; [@B66]), and cancer pain ([@B69]). Activation of peripheral M/K~v~7 channels significantly relives gout pain ([@B70]). Thus, suppression of neuronal excitability via augmentation of peripheral M/K~v~7 currents is a valuable analgesic strategy.

Itch, also known as pruritus, is an uncomfortable everyday experience that evokes a desire to scratch ([@B17]). Itch is commonly caused by chemical pruritogens ([@B17]); meanwhile, itch is also a prominent symptom of many diseases, such as dry skin ([@B46]), psoriasis ([@B22]), and atopic/allergic dermatitis ([@B4]), as well as patients with system disease such as chronic cholestatic liver disease ([@B9]) and renal disease ([@B54]). Understanding the neural basis of itch at the molecular, cellular, and circuit levels can identify new therapeutic targets to treat this devastating symptom ([@B40]). Mammals appear to have evolved two forms of itch: (i) chemical itch, which is activated by chemical mediators such as histamine (HIS) and chloroquine (CQ) and can be effectively gated by noxious painful stimuli ([@B28]), and (ii) mechanical itch, which is evoked by light mechanical stimuli such as when insects or parasites come in contact with the skin ([@B7]; [@B17]). Mechanical itch transmission is gated by a population of spinal inhibitory interneurons that expressed neuropeptide Y (NPY) ([@B7]). Loss of Merkel cells and associated mechanosensitive Piezo2 channels in the skin alleviates the activity of these inhibitory NPY interneurons and leads to mechanical itch ([@B24]). TRP channels such as TRPV1 and TRPA1 expressed in peripheral DRG pruritic neurons can be activated by G-protein-coupled pruriceptors (i.e., HIS-H1 receptor/H4 receptor, Serotonin-H7 receptor, CQ-MrgprA3 receptor), hence initiate itch sensation ([@B17]).

The fundamental step for different sensation generation including pain and itch is that irritants excite sensory neurons through the corresponding receptors and/or ion channels. Given the crucial role of M/K~v~7 currents in controlling neuronal excitability of sensory neurons, we hypothesize that M/K~v~7 may be involved in pruritogen-induced itch sensation. In the present study, itch-like behavior induced by several pruritogens such as CQ, serotonin (5-hydroxytryptamine, 5-HT), capsaicin (CAP), HIS, carvacrol (CAR), and β-alanine (β-ALA) have been measured. We demonstrate that CQ acts as a novel inhibitor of M/K~v~7 currents and its inhibition of M/K~v~7 currents at least partially contributes to CQ-induced itch in mice.

Materials and Methods {#S2}
=====================

Animals {#S2.SS1}
-------

Male C57B/J mice (6--8 weeks old; 20--25 g) were used. Mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and housed with a stable humidity (55 ± 15%) with free access to food/water in a 12/12 h light--dark cycle at room temperature (22--24°C), according to the guidelines of the local Animal Care and Use Committee at Hebei Medical University (Shijiazhuang, China).

Chemicals and Antibodies {#S2.SS2}
------------------------

All chemicals except β-ALA were purchased from Sigma (Sigma-Aldrich LLC, St. Louis, MO, United States). β-ALA was purchased from Beijing Brinway Technology Co. (Beijing, China). Antibodies specific to mouse K~v~7.2 subunit and mouse MrgprA were purchased from Abcam (Ambridge, United Kingdom). Goat anti-rabbit (Fluorescein 5-isothiocyanate, FITC) and Goat anti-mouse (Tetramethylrhodamine, TRITC) were purchased from Jackson ImmunoResearch Inc. (Baltimore, United States). 4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Protein Tech Group, Inc. (Wu Han, China).

Itch Behavior Test {#S2.SS3}
------------------

The itch-like behavior test was performed as previously described ([@B50]; [@B62]). Briefly, for assessing CQ-evoked itch behavior, mice received a subcutaneous injection into the cheek (20 μl) or neck (50 μl), with 200 μg CQ dissolved in saline (the concentrations were 20 and 8 mM, respectively). Mice were videotaped for 30 min following the injection. The number of scratch bouts were quantified over a 30-min period. One bout of scratching was defined as an episode in which a mouse lifted its hind paw and scratched continuously for any length of time, until the hind paw was returned to the floor or to the mouth. For assessing XE991 (a specific M/K~v~7 channel blocker)-evoked itch-like behaviors, mice received a subcutaneous injection into the cheek (0.1 or 1 mM, 20 μl) or neck (0.1 or 1 mM, 50 μl). Pruritogen such as 5-HT (1 mM, 50 μl)-, CAP (10 μM, 50 μl)-, HIS (90 mM, 50 μl)-, CAR (70 mM, 50 μl)-, and β-ALA (50 mM, 50 μl)-induced itch-like behaviors by subcutaneous injection into the neck were measured, respectively.

Rota-Rod Test {#S2.SS4}
-------------

Rota-rod test was performed as previously described ([@B13]) to assess motor coordination in mice. Briefly, mice were trained to remain on a treadmill device (Jixing Rota-Rod, Hebei, China) with slowly revolving rods of 5 cm diameter at 20 rpm for 180 s. Mice that were able to remain on the rod for 180 s or longer were selected and divided into three groups of five mice per group. Group I received saline, while groups II and III received RTG (20 mg/kg) and TA (16 mg/kg) by intraperitoneal injection, respectively. Thirty minutes after the treatment, mice were placed individually on the rod at intervals of 30 min, up to 60 min. If an animal failed more than once to remain on the rod for 3 min, the test was considered positive, meaning there was a lack of motor coordination.

Immunostaining {#S2.SS5}
--------------

Mice were transcardially perfused with 4% PFA under depth of anesthesia (2% sodium pentobarbital, 30 mg/kg). DRGs were removed and stored in 4% PFA followed by embedding in OCT (SAKURA, Japan). Ten-micrometer DRG sections were cut using a freezing microtome (Leica, Germany). Sections were washed once with 0.1 mol/L PBS (Beijing Solarbio Science & Technology Co., Ltd.) and punched for 30 min in 37°C with 0.3% Triton X-100/PBS buffer and blocked for 1 h with blocking buffer (10% goat serum in 0.1 mol/L PBS). Primary antibodies were diluted in 0.1% Triton X-100/PBS buffer before overnight incubation at 4°C. The second day, sections received three additional washes in PBS before incubation with secondary antibodies for 2 h at 37°C. Sections were washed three times with PBS and placed on microscope slides in Vectashield with DAPI (Southern Biotech). Staining was visualized and captured using a laser scanning confocal microscope (Leica SP5, Leica, Germany).

Cell Culture {#S2.SS6}
------------

Primary cultures of DRG neurons were prepared from 6- to 8-week-old male mice (20--25 g). Briefly, mice were anesthetized with isoflurane and sacrificed by decapitation. DRGs were rapidly dissected out bilaterally and incubated with 0.2% collagenase and 0.5% dispase for 1 h at 37°C in minimum essential medium for suspension culture (Thermo Fisher Scientific, Inc., Waltham, MA, United States). After digestion and trituration to dissociate neurons, DRG neurons were plated on glass coverslips pre-coated with poly-D-lysine (12.5 μg/ml) and laminin (20 μg/ml in Hanks' buffered salt solution, BD Biosciences). The cells were cultured in minimum essential medium (Thermo Fisher Scientific, Inc., Waltham, MA, United States) that contained 2.5S NGF (10 ng/ml; Roche Applied Science, Indianapolis, IN, United States), 5% heat-inactivated horse serum (JRH Biosciences, Lenexa, KS, United States), uridine/5-fluoro-2′-deoxyuridine (10 μM), 8 mg/ml glucose, and 1% vitamin solution (Thermo Fisher Scientific, Inc., Waltham, MA, United States). The cultures were maintained in an incubator at 37°C with a humidified atmosphere of 95% air + 5% CO~2~. Cells were used for patch clamp recordings after culturing for 2 days.

Electrophysiology {#S2.SS7}
-----------------

Whole-cell mode patch recordings in voltage- and current-clamp configurations were performed at room temperature (22--24°C). Coverslips with cultured neurons were placed in a 0.5-ml recording chamber. The recording chamber was mounted on a stage of an Olympus IX71 inverted microscope (Olympus Corporation, Tokyo, Japan) and cells were continuously perfused at 2 ml/min with bath solution. CQ was applied through bath solution perfusion. The bath solution contained (in mM): 145 NaCl, 5 KCl, 2 MgCl~2~, 2 CaCl~2~, 10 glucose, and 10 HEPES, with an osmolarity of 320 mOsm and a pH of 7.35. The intracellular solution contained (in mM): 150 KCl, 2.4 MgCl~2~, 0.5 CaCl~2~, 5 EGTA, 10 HEPES, 5.0 Na~2~ATP, and 0.33 GTP-Tris salt, with a pH of 7.35 and an osmolarity of 320 mOsm. The recording electrodes were fabricated from thin wall borosilicate glass capillaries using a Flaming P-97 puller (Sutter Instrument Co., Novato, CA, United States) and had resistances of 3--5 MΩ. Signals were recorded with an Axonpatch 700B amplifier, filtered at 2 kHz, and sampled at 5 kHz using pCLAMP 10.7 (Axon Instruments; Molecular Devices, LLC, Sunnyvale, CA, United States). The protocol used to study M/K~v~7 currents of DRG neurons was as follows: the cells were held at −20 mV following a 1-s hyperpolarizing step to −60 mV every 4 s ([@B30]). We used the current-clamp method to record the APs of DRG neurons. Continuous current-clamp recording with no current injection was used for monitoring of membrane potential (Vm). For recording of APs, cells were held at 0 pA and the APs were elicited by current injection at near the twofold rheobase for 0.5 s. The bath solution and internal solution used to record neuronal APs was the same as that used for M/K~v~7 current recordings. Whole-cell patch clamp recording data were analyzed using Clampfit 10.7 software (Axon Instruments; Molecular Devices, LLC, Sunnyvale, CA, United States).

Calcium Imaging {#S2.SS8}
---------------

DRG neurons were loaded with 2 μM fluo-4-acetoxymethyl ester (fluo-4-AM; Molecular Probes; Thermo Fisher Scientific, Inc.) at 37°C for 30 min. After loading, the cells were washed three times with Dulbecco's PBS to remove the extracellular dye, and then placed in a chamber mounted on the stage of laser scanning confocal microscope (Leica TCS SP5; Leica Microsystems GmbH, Wetzlar, Germany). The cells were incubated with the same bath solution as the patch clamp experiment. Fluo-4-AM loaded calcium signals were excited at a wavelength of 488 nm, and the emission fluorescence was measured at 530 nm. The calcium signals induced by drug application in bath solution were measured. Dynamic signals were recorded at an interval of 2 s and normalized to the initial fluorescence value.

Statistics {#S2.SS9}
----------

Data were presented as the mean ± SEM for the indicated number of independently conducted experiments, and analyzed with Origin 9.1 software (OriginLab Corporation, Northampton, MA, United States) and SPSS 13.0 (SPSS Inc., Chicago, IL, United States). Statistical significance was evaluated using either a Student's *t*-test or a one-way analysis of variance followed by Dunnett's *post-hoc* test for multiple groups. For the behavioral data that were not in normal distribution, Mann--Whitney *U* test was used to evaluate the statistical significance. *p* \< 0.05 was considered to indicate a statistically significant difference.

Results {#S3}
=======

Inhibition of M/K~v~7 Channel Activity Induces Itch-Like Behavior in Mice {#S3.SS1}
-------------------------------------------------------------------------

To determine the role of M/K~v~7 channel in the generation of itch sensation, itch-like behavior test *in vivo* was performed in mice. Intracutaneous injection of 1 mM XE991, a selective M/K~v~7 channel blocker ([@B61]) into the nape of neck, elicited obvious scratching behavior ([Figure 1A](#F1){ref-type="fig"}). The scratching behavior induced by XE991 was significantly suppressed by the specific M/K~v~7 channel opener retigabine (RTG) ([@B58]; [Figure 1B](#F1){ref-type="fig"}). These results suggest that inhibition of M/K~v~7 channel activity induces itch-like behavior in mice.

![Inhibition of M/K~v~7 channel activity induces itch in mice. **(A)** Intracutaneous injection of XE991 (1 mM, 50 μl) into the nape of neck induces scratching behavior. **(B)** Intracutaneous pre-injection of M/K~v~7 channel opener retigabine (RTG, 10 mg/kg, 100 μl) suppresses XE991-induced scratching behavior. **(C,D)** Intracutaneous injection of XE991 into the cheek induces scratching **(C)** and pain behavior **(D)**, respectively. As a positive control, pruritogen CQ (20 mM, 20 μl) only induces itch **(C)** but not pain behavior **(D)**. **(E,F)** Intracutaneous pre-injection of RTG (15 mM, 25 μl) and tannic acid (TA, 5 mM, 25 μl) significantly suppresses XE991 (1 mM)-induced scratching **(E)** and pain behavior **(F)** in cheek model. Intracutaneous pre-injection of naltrexone (1 mg/kg, 25 μl) only inhibits XE991 (1 mM)-induced scratching **(E)** but not pain behavior **(F)**. As a positive control, CQ (20 mM, 20 μl) only induces itch behavior **(E)**, and it can be reversed by naltrexone. Data are shown as mean ± SEM (*n* = 8 per group in **A--D** and *n* = 5 per group in **E** and **F**). The statistical significance was evaluated using Student's *t-*test. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00105-g001){#F1}

To distinguish the itch-like behavior from the painful behavior that could also be induced by inhibition of M/K~v~7 channel activity ([@B37]; [@B20]), agents were intracutaneously injected into the cheek (known as "cheek model of itch"). In this case, the itch-like behavior will be demonstrated by hindpaw scratching, whereas the painful behavior will be demonstrated by forepaw wiping, respectively ([@B50]; [@B62]). Indeed, cheek injection of 0.1 and 1 mM XE991 both induced significant scratching behavior ([Figure 1C](#F1){ref-type="fig"}). However, only 1 mM XE991 induced pain behavior ([Figure 1D](#F1){ref-type="fig"}). As a positive control, cheek injection of CQ (20 mM) elicited obvious scratching ([Figure 1C](#F1){ref-type="fig"}) but not pain behavior ([Figure 1D](#F1){ref-type="fig"}). In the cheek model, RTG and another M/K~v~7 channel opener tannic acid (TA) ([@B67]) were used to further determine the role of M/K~v~7 channel in itch and pain. XE991 (1 mM)-induced scratching and pain behavior were significantly suppressed by intracutaneous pre-injection of RTG (15 mM) and TA (5 mM) ([Figures 1E,F](#F1){ref-type="fig"}). Naltrexone (1 mg/kg), a well-known itch antagonist ([@B56]), significantly inhibited 1 mM XE991-induced scratching but not pain behavior by intracutaneous pre-injection ([Figures 1E,F](#F1){ref-type="fig"}). CQ-induced scratching behavior was also significantly suppressed by intracutaneous pre-injection of naltrexone (1 mg/kg) ([Figures 1E,F](#F1){ref-type="fig"}). On the other hand, rota-rod test was performed to exclude the possibility that M/K~v~7 channel inhibition-induced itch and pain were suppressed by M/K~v~7 channel openers through inhibiting the central nervous system (CNS) and motor function. As shown in [Table 1](#T1){ref-type="table"}, intraperitoneal injection of RTG (20 mg/kg) or TA (16 mg/kg) did not affect CNS and motor function at the time points when the itch behavior tests were performed ([Table 1](#T1){ref-type="table"}). Taken together, these results indicate that inhibition of M/K~v~7 channel activity contributes to not only pain but also itch sensation generation.

###### 

Effects of intraperitoneal injection of RTG and TA on rota-rod test in mice.

  Treatment      Post-treatment (min)                     
  -------------- ---------------------- ----- ----------- -----
  Saline         \>180.0 s              0.0   \>180.0 s   0.0
  RTG 20 mg/kg   \>180.0 s              0.0   \>180.0 s   0.0
  TA 16 mg/kg    \>180.0 s              0.0   \>180.0 s   0.0

Agents were administrated by intraperitoneal (i.p.) injection. Rota-rod test was performed after treatment for 30 and 60 min, respectively. Thirty minutes was used because it was the start time to observe the effects of CQ after i.p. administration of RTG or TA in the experiments. Results are presented as mean ± SEM. No significant difference between saline and treated groups; one-way analysis of variance (ANOVA) followed by Dunnett's post-hoc test for multiple comparisons; n = 5 in each group.

M/K~v~7 Channel Openers Selectively Suppress CQ-induced Itch-Like Behavior in Mice {#S3.SS2}
----------------------------------------------------------------------------------

To determine the role of M/K~v~7 channel in CQ-induced itch sensation, the *in vivo* behavioral test was performed in mice whose nape of neck was intradermally injected with CQ; the itch sensation was identified by the scratching on the skin with hindpaws. RTG and TA were tested in the scratching behavioral measurement. Intradermal injection of CQ significantly increased the scratching bouts to 263 ± 24 (*n* = 8) from 23 ± 8 (*n* = 8, *p* \< 0.001) in control group mice ([Figure 2A](#F2){ref-type="fig"}). Intraperitoneal pre-administration of RTG or TA effectively prevented CQ-induced scratching behavior in a dose-dependent manner ([Figures 2A,C](#F2){ref-type="fig"}). For example, pre-administration of RTG at 5, 10, and 20 mg/kg significantly reduced the scratching bouts of CQ group from 263 ± 24 to 185 ± 20 (*n* = 8, *p* \< 0.05), 151 ± 33 (*n* = 8, *p* \< 0.05), and 112 ± 30 (*n* = 8, *p* \< 0.01), respectively ([Figure 2A](#F2){ref-type="fig"}). Pre-administration of TA at 4, 8, and 16 mg/kg also significantly reduced CQ-induced scratching bouts from 236 ± 35 (*n* = 8) to 104 ± 16 (*n* = 8, *p* \< 0.05), 73 ± 21 (*n* = 8, *p* \< 0.01), and 18 ± 6 (*n* = 8, *p* \< 0.001), respectively ([Figure 2C](#F2){ref-type="fig"}). Furthermore, intradermal pre-injection of RTG and TA at the nape of neck significantly reduced the scratching bouts induced by CQ injected at the same site from 252 ± 22 (*n* = 8) and 211 ± 44 (*n* = 8) to 143 ± 23 (*n* = 8, *p* \< 0.01) and 103 ± 13 (*n* = 8, *p* \< 0.01), respectively ([Figures 2B,D](#F2){ref-type="fig"}). These results indicate that the M/K~v~7 channel is involved in the CQ-induced itch sensation.

![Activation of M/K~v~7 channel suppresses CQ-evoked itch. Intraperitoneal (i.p.) pre-injection of RTG **(A)** and TA **(C)** suppresses CQ (8 mM, 50 μl)-evoked scratching behavior in a dose-dependent manner. Intradermal (i.d.) pre-injection of RTG (20 mg/kg, 100 μl) **(B)** and TA (16 mg/kg, 100 μl) **(D)** reduces the same site injection of CQ (8 mM, 50 μl)-evoked scratching behavior. Data are shown as mean ± SEM (*n* = 8 per group). The statistical significance was evaluated using one-way analysis of variance followed by Dunnett's *post-hoc* test for comparation among multiple groups and Student's *t-*test between two groups. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\*^/\#\#\#^*p* \< 0.001.](fnmol-13-00105-g002){#F2}

We then examined whether the M/K~v~7 channel is also involved in itch sensation induced by other pruritogens. For this, 5-HT, CAP, HIS, CAR, and β-ALA were intradermally injected into the nape of neck, respectively. All the above compounds elicited obvious itch-like scratching behavior ([Figures 3A--E](#F3){ref-type="fig"}). Intraperitoneal pre-administration of RTG or TA significantly prevented this compound-induced scratching behavior in a dose-dependent manner ([Figures 3A--E](#F3){ref-type="fig"}). Taken together, these results indicate that augmentation of M/K~v~7 channel activity significantly suppresses the itch sensation induced by the above compounds.

![Effects of M/K~v~7 channel activation in several pruritogens-evoked itch. I.p. pre-injection of RTG (left) and TA (right) suppresses serotonin (5-HT, 1 mM, 50 μl) **(A)**, capsaicin (CAP, 10 μM, 50 μl) **(B)**, histamine (His, 90 mM, 50 μl) **(C)**, carvacrol (CAR, 70 mM, 50 μl) **(D)**, and β-alanine (β-ALA, 50 mM, 50 μl) **(E)**-evoked scratching behavior in a dose-dependent manner, respectively. Data are shown as mean ± SEM (the *n* number in each group is indicated). For the data that exhibited normal distribution, the statistical significance was evaluated using Student's *t-*test between two groups; for the data that were not in normal distribution (\#), the statistical significance was evaluated using Mann--Whitney *U* test between two groups. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00105-g003){#F3}

CQ Inhibits M/K~v~7 Currents Through Increasing Intracellular Ca^2+^ in Mouse DRG Neurons {#S3.SS3}
-----------------------------------------------------------------------------------------

To determine the effect of CQ on M/K~v~7 currents, whole-cell patch-clamp recordings were performed in cultured mouse DRG neurons. Bath application of CQ significantly inhibited M/K~v~7 currents in a concentration-dependent manner ([Figures 4A,B](#F4){ref-type="fig"}). CQ initiated its inhibition on M/K~v~7 currents at 0.01 mM and reached its maximal inhibition at 100 mM ([Figure 4B](#F4){ref-type="fig"}). The half maximum inhibitory concentration (IC~50~) was at 1.0 ± 0.4 mM ([Figure 4B](#F4){ref-type="fig"}). However, the current--voltage (*I*--*V*) curve of M/K~v~7 was not affected by CQ ([Figure 4C](#F4){ref-type="fig"}). In addition, immunostaining assay showed that M/K~v~7 channel subunit K~v~7.2 was co-localized with MrgprA receptor (CQ receptor) in mouse DRG neurons ([Supplementary Figure 1](#FS1){ref-type="supplementary-material"}).

![CQ inhibits M/K~v~7 currents in mice DRG neurons. **(A)** Representative time course of CQ (1 mM)-induced inhibition of M/K~v~7 currents (left). Current traces are shown (right). XE991 (10 μM) was used as positive control to inhibit M/K~v~7 currents. **(B)** The concentration--effect relationship curve for CQ-induced inhibition of M/K~v~7 currents is shown. IC~50~ = 1.0 ± 0.4 mM (*n* = 6, 6, 21, 5, 5 at each concentration of CQ, respectively). **(C)** CQ (1 mM) has no significant effect on current--voltage (*I--V*) curve of M/K~v~7 channel. The statistical significance was evaluated using one-way analysis of variance followed by Dunnett's *post-hoc* test for multiple comparations.](fnmol-13-00105-g004){#F4}

For the signaling molecules involved in M/K~v~7 current inhibition, three mechanisms have been proposed, PIP~2~ depletion, increment of intracellular Ca^2+^, and PKC phosphorylation, which are the downstream signals of phospholipase C (PLC) activation ([@B26]; [@B19]). Previous studies have demonstrated that CQ increases intracellular concentration of Ca^2+^ through activation of TRPA1 channels ([@B62]; [@B59]). We examined the effect of CQ on mouse DRG neurons using Ca^2+^-imaging assay. Specific TRPA1 agonist allyl isothiocyanate (AITC) was used to indicate the DRG neurons with TRPA1-positive response. As shown in [Figure 5](#F5){ref-type="fig"}, CQ significantly increased intracellular Ca^2+^ in mouse DRG neurons ([Figure 5A](#F5){ref-type="fig"}). Eighty-three percent (44 out of 53) of mouse DRG neurons that responded to CQ were TRPA1-positive DRG neurons ([Figures 5A,B](#F5){ref-type="fig"}). Excluding the Ca^2+^ from the bath solution eliminated CQ-induced increase of intracellular Ca^2+^ ([Figures 5C,D,F](#F5){ref-type="fig"}). HC-030031, a specific TRPA1 channel blocker, significantly inhibited CQ-induced increase of intracellular Ca^2+^ ([Figures 5E,F](#F5){ref-type="fig"}). These results indicate that CQ-induced intracellular Ca^2+^ increase in mouse DRG neurons is due to the TRPA1 activation-induced Ca^2+^ influx.

![CQ increases intracellular Ca^2+^ through TRPA1-mediated Ca^2+^ influx in mice DRG neurons. **(A)** Representative traces from six different DRG neurons with calcium-imaging assay. Allyl isothiocyanate (AITC, 10 mM)-responsive DRG neurons indicate TRPA1-positive neurons. **(B)** The Venn diagram illustrates the relationships of CQ-, AITC (TRPA1^+^)-responsive neurons in adult DRG. The sizes of the circles are proportional to the sizes of the cell populations. CQ can increase intracellular Ca^2+^ in the presence **(C)** but not in the absence **(D)** of extracellular Ca^2+^ (2 mM). **(E)** Selective inhibition of TRPA1 by HC-030031 reduces CQ-induced increase of intracellular Ca^2+^. **(F)** Summary data of CQ-induced increase of intracellular Ca^2+^ in normal bath solution, Ca^2+^-free solution, and normal bath solution contained HC-030031, respectively. Data are shown as mean ± SEM (the *n* number in each group is indicated). The statistical significance was evaluated using Student's *t-*test for comparison between two groups. \*\*\**p* \< 0.001.](fnmol-13-00105-g005){#F5}

Consistently, CQ-induced inhibition of M/K~v~7 currents was significantly attenuated by perfusing cells with Ca^2+^-free bath solution and HC-030031, respectively ([Figures 6A--C,F](#F6){ref-type="fig"}). For example, Ca^2+^-free bath solution significantly reduced the CQ (1 mM)-induced inhibition of M/K~v~7 current from 45% (*n* = 15) to 24% (*n* = 8, *p* \< 0.01), while HC-030031 significantly reduced the inhibition to 23% (*n* = 5, *p* \< 0.05) ([Figure 6F](#F6){ref-type="fig"}). However, bath application of U73122, a PLC inhibitor, showed no obvious effects on CQ-induced inhibition of M/K~v~7 currents (36%; *n* = 5, *p* \> 0.05) ([Figures 6D,F](#F6){ref-type="fig"}). Furthermore, activation of TRPA1 with AITC (1 mM) significantly inhibited M/K~v~7 currents by 41% (*n* = 4), and this effect was reduced to 17% (*n* = 4, *p* \< 0.01) by 10 μM RTG ([Figures 6E,F](#F6){ref-type="fig"}). Taken together, these results suggest that CQ-induced inhibition of M/K~v~7 currents in mouse DRG neurons is due to the CQ-induced increase of intracellular Ca^2+^, which is through TRPA1 activation-mediated Ca^2+^ influx. PIP~2~ depletion and PKC phosphorylation, the downstream signals of PLC, may not be involved in CQ-mediated inhibition of M/K~v~7 currents.

![CQ inhibits M/K~v~7 currents through TRPA1-mediated Ca^2+^ influx in mice DRG neurons. **(A)** Representative time course of CQ (1 mM)-induced inhibition of M/K~v~7 currents. **(B)** Excluding the Ca^2+^ from the bath solution eliminates CQ-induced inhibition of M/K~v~7 currents. **(C)** Selective inhibition of TRPA1 by HC-030031 suppresses CQ-induced inhibition of M/K~v~7 currents. **(D)** Inhibition of phospholipase C by U73122 does not suppress CQ-induced inhibition of M/K~v~7 currents. **(E)** Selective activation of TRPA1 by AITC inhibits M/K~v~7 currents, and this effect can be reduced by RTG. **(F)** Summary data from **(A--E)**. Data are shown as mean ± SEM (the *n* number in each group is indicated). The statistical significance was evaluated using Student's *t-*test for comparison between two groups. \**p* \< 0.05, \*\**p* \< 0.01.](fnmol-13-00105-g006){#F6}

CQ Enhances the Excitability of Mouse DRG Neurons {#S3.SS4}
-------------------------------------------------

M/K~v~7 currents play a key role in regulation of neuronal excitability. As a result, inhibition of M/K~v~7 currents causes membrane depolarization and reduces the threshold and rheobase of action potentials ([@B19]). We next tested whether CQ increased the excitability of mouse DRG neurons through inhibition of M/K~v~7 currents as demonstrated above. The membrane potential of mouse DRG neurons was first recorded using the current clamp method ([Figures 7A--C](#F7){ref-type="fig"}). CQ depolarized the membrane potential in a concentration-dependent manner ([Figures 7A,B](#F7){ref-type="fig"}). At 1 mM, CQ significantly depolarized the membrane potential from −59 ± 1 mV (*n* = 31) to −49.5 ± 1.2 mV (*n* = 37, *p* \< 0.001) ([Figures 7C,D](#F7){ref-type="fig"}). Furthermore, the CQ-induced depolarization of membrane potential could be reversed (to 59 ± 1.2 mV, *n* = 14, *p* \< 0.001) by the M/K~v~7 channel opener RTG ([Figures 7C,D](#F7){ref-type="fig"}). Then, the effect of CQ on action potentials (APs) of mouse DRG neurons was tested; APs were induced by different levels of current injection. For this, the threshold (the distance from resting membrane potential to threshold membrane potential) and the rheobase for eliciting APs and AP fire numbers was addressed. The threshold was significantly reduced from 28.8 ± 1.4 mV (*n* = 7) of control group to 19.3 ± 0.9 mV (*n* = 5, *p* \< 0.001) by CQ ([Figures 8A,B](#F8){ref-type="fig"}), which was mostly reversed by RTG (30 ± 1.1mV, *n* = 4, *p* \< 0.001) ([Figures 8A,B](#F8){ref-type="fig"}). Similarly, CQ reduced the rheobase from 73 ± 11 pA (*n* = 7) to 39 ± 9 pA (*n* = 5, *p* \< 0.05), and RTG reversed this CQ-induced reduction of the rheobase (to 79 ± 15 pA, *n* = 6, *p* \< 0.05) ([Figure 8C](#F8){ref-type="fig"}). Finally, numbers of APs induced by a 120-pA current injection were increased from 3.3 ± 1.3 (*n* = 6) to 9.0 ± 1.2 by CQ (*n* = 4, *p* \< 0.05) ([Figures 8A,D](#F8){ref-type="fig"}), which was again reversed by RTG (to 2.2 ± 0.5, *n* = 6, *p* \< 0.01) ([Figures 8A,D](#F8){ref-type="fig"}). These results indicate that CQ enhances the excitability of mouse DRG neurons through its inhibition of M/K~v~7 currents.

![RTG reverses CQ-induced depolarization of the membrane potential in DRG neurons. **(A)** Representative trace shows that CQ depolarizes membrane potential (Vm) in a concentration-dependent manner. **(B)** Summary data of depolarization of membrane potential by different concentration of CQ. **(C)** RTG reverses CQ (1 mM)-induced depolarization of membrane potential. **(D)** Summary data of resting membrane potential (RMP). Data are shown as mean ± SEM (the *n* number in each group is indicated). The statistical significance was evaluated using Student's *t-*test for comparison between two groups. \*\*\**p* \< 0.001.](fnmol-13-00105-g007){#F7}

![RTG reverses CQ-induced hyperexcitability of DRG neurons. **(A)** Representative samples show that CQ induces hyperexcitability (middle) compared with control (Cont, left), while RTG reverses CQ-induced the neuronal hyperexcitability (right). **(B)** RTG increases CQ (1 mM)-induced reduction of the threshold (*n* = 7, Cont group; *n* = 5, CQ group; and *n* = 4, CQ + RTG group). **(C)** RTG increases CQ (1 mM)-induced reduction of the rheobase. *n* = 7, 5, and 6 in Cont, CQ, and CQ + RTG group, respectively. **(D)** RTG reduces CQ (1 mM)-induced increase of action potentials (spikes) number. *n* = 6, 4, and 6 in Cont, CQ, and CQ + RTG group, respectively. Data are shown as mean ± SEM (the *n* number in each group is indicated). The statistical significance was evaluated using Student's *t-*test for comparison between two groups. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00105-g008){#F8}

Discussion {#S4}
==========

For chemical itch, a better understanding of peripheral mechanisms is emerging ([@B17]), and to this we add a new mechanism of M/K~v~7 channels. The major findings of this study are as follows: (1) inhibition of M/K~v~7 potassium currents causes itch sensation; (2) CQ is an inhibitor of M/K~v~7 currents, and inhibitory mechanism involves TRPA1-mediated Ca^2+^ influx; (3) CQ-induced inhibition of M/K~v~7 induces hyper-excitability of DRG neurons, which is likely the mechanism for CQ-induced itch sensation. It is well-known that peripheral M/K~v~7 channels play a key role in pain sensation. Augmentation of its expression or activity is an effective analgesic strategy ([@B19]). Interestingly, we found in this study that inhibition of M/K~v~7 also leads to itch generation under the "cheek model of itch" and "neck model of itch" measurements, and activators of M/K~v~7 channels alleviate itch behavior caused by CQ and other pruritogens. This is the first time, to our best knowledge, to describe the relationship between M/K~v~7 channel and itch. In the peripheral sensory system, increasing the expression and/or the activity of M/K~v~7 channels may have great benefit for anti-pruritus.

Among the pruritogens we tested in this study, CQ is a drug that has long been used in the treatment and prevention of malaria. One major side effect of CQ is HIS-independent itch ([@B23]; [@B1]; [@B27]). Recently, the molecular mechanisms for CQ-induced itch has been studied. One subpopulation of dorsal horn neurons in the spinal cord that specifically expresses gastrin-releasing peptide receptor (GRPR) mediates CQ- and other chemical-induced itch ([@B57]). In the primary DRG sensory neurons, mouse MrgprA3 and human MrgprX1 are functioned as the predominant receptors for CQ ([@B39]). Mrgprs (known as the Mas-related G protein-coupled receptors) are a family of orphan GPCRs that are restricted to express in the subsets of small-diameter sensory neurons in DRG ([@B18]). Since all of the molecular correlates of M/K~v~7 channel, KCNQ2/3/5, were widely expressed in DRG neurons including small- and large-diameter sensory neurons ([@B44]; [@B19]), it will be not surprised to find that M/K~v~7 channels are co-localized with CQ receptors. Indeed, our results show that MrgprA receptors are co-localized with K~v~7.2 subunit in mouse DRG neurons. CQ activates TRPA1 channel through the activation of the MrgprA3-G~βγ~ pathway, which evokes itch ([@B62]). Consistent with the previous study, our results demonstrate that CQ increases intracellular Ca^2+^ concentration by Ca^2+^ influx in a TRPA1-dependent manner in mouse DRG neurons. Furthermore, it is likely that CQ uses this mechanism but not MrgprA3/PLC pathway to inhibit M/K~v~7 currents, because removing extracellular Ca^2+^ or blocking TRPA1 channel both significantly suppresses the CQ-induced inhibition of M/K~v~7 currents, whereas blocking PLC activity does not affect CQ-mediated inhibition of M/K~v~7 currents. Interestingly, TRPA1 activation is likely sufficient to inhibit M/K~v~7 currents directly. It is well-known that increase of intracellular Ca^2+^ induces M/K~v~7 inhibition ([@B15]; [@B25]; [@B32]). Consistent with our observation, TRPV1-mediated Ca^2+^ influx has been shown to inhibit M/K~v~7 currents ([@B68]). It is worth noting that CQ still inhibited M/K~v~7 currents in Ca^2+^-free bath solution or in the presence of TRPA1 blocker. This phenomenon indicates that CQ may exhibit non-specific, direct inhibition on M/K~v~7 currents in mouse DRG neurons. Similar to CQ, 5-HT activates TRPA1 channels but through HT receptor 7 (HTR7)--Adenylyl Cyclase (AC)--cAMP pathway that evokes itch sensation ([@B41]). Genetic knockout of HTR7 completely abolished low dose of 5-HT-induced itch and partially reduced scratching in mouse model of atopic dermatitis ([@B41]). Thus, both CQ and 5-HT target to activate TRPA1 channel and thereby enhance neuronal excitability to evoke itch sensation ([@B62]; [@B41]). However, whether 5-HT/HTR7/TRPA1-mediated Ca^2+^ influx inhibits M/K~v~7 currents and then contributes to 5-HT-induced itch remains to be determined.

HIS-induced itch sensation is due to exciting sensory neurons through the activation of H1 or H4 receptor ([@B21]; [@B53]). Direct activation of TRPV1 channel by HIS-H1R underlies HIS induced itch ([@B49]). HIS also inhibits M/K~v~7 currents through H1R--PLC pathway-induced membrane PI(4,5)P~2~ hydrolysis in rat SCG neurons ([@B36]). Moreover, TRPV1 channel-mediated Ca^2+^ influx inhibits M/K~v~7 currents ([@B68]). Thus, involvement of M/K~v~7 inhibition in HIS-induced itch sensation is a logical explanation. TRPV1, when activated by its agonist CAP ([@B11], [@B10]), also evokes moderate itch ([@B51], [@B52]), besides its being well-known as a nociceptive receptor ([@B11], [@B10]).

β-ALA is reported to inhibit M/K~v~7 currents through MrgprD receptor in rat DRG neurons ([@B14]); also, this may not be the case in mice DRG neurons ([@B47]). Indeed, β-ALA can evoke HIS-independent itch sensation and increase intracellular Ca^2+^ concentration, both through MrgprD receptor in mice, but whether M/K~v~7 channels are involved remains unclear ([@B38]). Nonetheless, we show in this study that activation of M/K~v~7 channels also alleviates the β-ALA-induced itch behavior.

CAR is a natural compound that can specifically activate TRPV3 channels ([@B43]; [@B60]). TRPV3 is most abundantly expressed in skin keratinocytes and in cells surrounding hair follicles, where it plays an essential role in cutaneous sensation including thermal sensation, nociception, and itch, in addition to maintenance of the skin barrier and hair growth ([@B45]; [@B12]; [@B16]). In human, gain-of-function mutations of TRPV3 are associated with Olmsted syndrome, which is characterized by severe itch and palmoplantar and periorificial keratoderma ([@B33]; [@B34]). In rodents, gain-of-function mutations of TRPV3 are associated with skin inflammation and pruritus ([@B3]; [@B64]). In addition, itching behavior is suppressed in TRPV3 knockout mice ([@B63]). TRPV3 is unlikely to be distributed in sensory neurons of rodents ([@B45]). Thus, systemic application of M/K~v~7 opener, RTG, and TA, may indirectly reduce CAR/TRPV3-induced itch by suppressing the excitability of sensory neurons.

In conclusion, the results of this study strongly demonstrate that inhibition of M/K~v~7 currents induces itch. TRPA1-dependent inhibition of M/K~v~7 currents by CQ contributes to CQ-induced itch. These findings provide novel insight into the molecular basis of chemical itch that can be used to develop strategies to mitigate itch sensation.
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Co-localization of K~v~7.2 and MrgprA in mouse DRG neurons. **(A)** Representative images show that M/K~v~7 channel subunit K~v~7.2 is co-localized with MrgprA receptor (arrows, bottom merged) in mouse DRG neurons. Images in the bottom row are extended from the square regions in the up row./break Scale bar in each panel in up and bottom row is 75 and 25 μm, respectively.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

[^1]: Edited by: Wolfgang Liedtke, Duke University, United States

[^2]: Reviewed by: Hyosang Lee, Daegu Gyeongbuk Institute of Science and Technology (DGIST), South Korea; Hongzhen Hu, Washington University in St. Louis, United States

[^3]: ^†^These authors have contributed equally to this work
